SIRO Clinpharm expands operations into Malaysia

By Alexandria Pesic

- Last updated on GMT

Related tags: Contract research, Contract research organization, Clinical research, Clinical trial

SIRO Clinpharm, the Mumbai, India-based contract research organisation (CRO) has expanded its operations into Malaysia.

The company already maintains a strong presence across the region after forming strategic alliances with Taiwanese CRO, Virginia Contract Research, and South Korea-based clinical trials specialist, DreamCIS, in 2010.

Anjit Nair, SIRO’s vice president of clinical operations in Asia, explained the reasons behind the move.

“Besides advantages common to other Asian countries, what attracted us to Malaysia was a robust regulatory framework with complaint timelines strong government commitment towards clinical research and modern medical facilities.”

Highly developed

Rajenedra Talele, vice president of clinical operations in Asia, said SIRO had big plans to make the most of rapid growth in the region.

“Malaysia is a highly developed and fast growing clinical trials destination and we are extremely proud to be one of the first India headquartered CROs to announce its operations.”

He went on to reveal that the company’s first phase of service offerings will include clinical monitoring and project management activities.

Additional geography

Commenting on the announcement, Chetan Tamhankar, SIRO’s CEO, said the company had plans to expand into other Asian countries, and were already sizing up potential destinations.

“This expansion in Asia gives us an opportunity to immediately offer and additional geography to conduct clinical trials to our existing as well as potential clients,” ​he said.

From a futuristic expansion perspective, we are in the process of evaluating the Philippines and Thailand amongst other Asian countries.”

Potential partnership

Early in 2010 SIRO Clinpharm entered into talks with Indian healthcare company, Biocon over a potential partnership centred on Biocon’s Clingene contract research services business. However, Biocon backed out of talks later that year before an agreement could be reached.

SIRO Clinpharm has since expanded its operations across Europe, forming partnerships with UK regulatory affairs specialist, CambReg, and French early-stage contract drug development group, Mediscis Medical Science Services.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars